Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
View original at globenewswire.comCardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating Offi…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Ajay Aggarwal brings deep clinical development and operational expertise, with proven ability to advance programs from early research through late-stage development
60% confidenceJosh Muntner is a highly accomplished financial leader with strong track record of executing complex financings and building trusted relationships across the investment community
60% confidenceThere are no guarantees that onvansertib will be utilized or prove to be commercially successful, and no guarantees that future clinical trials will be completed or successful
60% confidenceCardiff has made meaningful progress advancing onvansertib in first-line RAS-mutant metastatic colorectal cancer and remains focused on delivering clinical data to support registrational program
60% confidenceCardiff Oncology aims to overcome treatment resistance and deliver improved clinical outcomes for patients by targeting tumor vulnerabilities
60% confidenceBuilding the right team to advance onvansertib is central to Cardiff's strategy and to ultimately delivering a potential new therapy to patients in need
60% confidenceClinical trials involve a lengthy and expensive process with uncertain outcome, and results of earlier studies may not be predictive of future trial results
60% confidence